What is the appropriate treatment for a flare after stopping dupilumab (Dupixent)?

Treatment of Atopic Dermatitis Flare After Stopping Dupilumab

When atopic dermatitis flares after discontinuing dupilumab, restart optimized topical therapy immediately with high-potency topical corticosteroids and/or topical calcineurin inhibitors to previously affected areas, and strongly consider reinitiating dupilumab if topical therapy fails to control the flare within 2-4 weeks.

Understanding Post-Dupilumab Flares

Flares after dupilumab discontinuation are common and expected. Recent data shows that 52.9% of patients experience skin lesion relapse after stopping dupilumab, with a median time to relapse of 457 days 1. This is significantly longer than JAK inhibitors (60 days), but relapse remains the norm rather than the exception. Only 5.1% of patients can maintain remission with topical therapy alone after discontinuing dupilumab 2.

The FDA label explicitly warns that "symptoms that were controlled by those medicines [may] come back" when discontinuing treatment 3. This is not a treatment failure—it reflects the chronic, relapsing nature of moderate-to-severe atopic dermatitis and the need for ongoing disease control.

Immediate Management Algorithm

Step 1: Optimize Topical Therapy

• Restart or intensify topical corticosteroids to all affected areas
• Use appropriate potency based on body site and severity
• Add topical calcineurin inhibitors (tacrolimus or pimecrolimus) for sensitive areas (face, intertriginous zones)
• Apply to both active lesions AND previously involved skin
• Continue basic skin care: emollients, trigger avoidance, appropriate bathing practices

Step 2: Assess Response at 2-4 Weeks

If inadequate control with optimized topicals:

• Reinitiate dupilumab at standard dosing (600 mg loading dose, then 300 mg every 2 weeks) 4
• Dupilumab remains the first-line systemic agent preferred by all guideline workgroup members 4
• Alternative systemic options include tralokinumab, JAK inhibitors (upadacitinib, abrocitinib), or phototherapy 4

Step 3: Consider Alternative Diagnoses

If the flare is atypical or refractory to treatment:

• Rule out allergic contact dermatitis (consider patch testing) 5
• Evaluate for secondary infection (bacterial, viral, fungal)
• Rarely, dupilumab can paradoxically induce psoriasiform eruptions—if suspected, biopsy and consider switching to alternative biologics 6

Key Clinical Considerations

Predictors of successful discontinuation (though rare) include 2:

• Lower baseline disease severity (POEM, EASI scores)
• Longer duration of dupilumab treatment (≥24 months vs. 12-13 months)
• Near-complete clearance (very low EASI) at time of discontinuation
• Lower baseline inflammatory markers (TARC, LDH)

Common pitfall: Attempting to discontinue dupilumab too early. Data suggests that even after 1 year of treatment, only 3.4% of patients maintain remission after stopping 2. If discontinuation is attempted, it should ideally be after ≥2 years of treatment with sustained complete or near-complete clearance 2.

Maintenance Strategy After Flare Control

Once the flare is controlled (whether with topicals alone or after reinitiating systemic therapy):

• Implement proactive maintenance therapy: Apply topical corticosteroids 1-2 times weekly OR topical calcineurin inhibitors 2-3 times weekly to previously involved skin 5
• This approach reduces subsequent flares and relapses 5
• Continue emollient use daily
• If dupilumab is reinitiated, maintain it long-term rather than attempting repeated discontinuation cycles

Special Populations

Patients with comorbid asthma: The FDA specifically warns not to adjust or stop asthma treatments when managing AD flares 3. If dupilumab was treating both conditions, reinitiation may be particularly important to prevent asthma exacerbations.

Patients on concurrent corticosteroids: Do not abruptly discontinue systemic corticosteroids if they were being used, as this can cause withdrawal symptoms 3.

Bottom Line

The evidence strongly suggests that most patients with moderate-to-severe AD will flare after dupilumab discontinuation. Rather than viewing this as a failure, recognize it as the natural disease course. Aggressive topical therapy should be the immediate response, but have a low threshold to reinitiate dupilumab if control is not rapidly achieved. Long-term maintenance therapy—whether systemic or intensive topical—is typically necessary for sustained disease control in this population.